{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:27:06Z","timestamp":1759411626077},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":664,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2000,3]]},"abstract":"<jats:p>Individuals with Haemophilia are at risk from hepatitis A virus (HAV) infection through exposure to blood products. Havrix<jats:sup>\u00ae<\/jats:sup>, an intramuscular hepatitis A vaccine, is currently recommended for the prevention of disease caused by hepatitis A virus. Because bleeding may complicate intramuscular injections in those with bleeding disorders, we conducted a randomized, Phase IV clinical trial to compare the safety and immunogenicity of Havrix<jats:sup>\u00ae<\/jats:sup> given by the subcutaneous (s.c) vs. intramuscular (i.m.) route. A total of 45 children with Haemophilia were vaccinated subcutaneously, while their 41 nonhaemophlic siblings were vaccinated intramuscularly, at a dose of 720 Elisa units (EL.U.) at time 0 and 6\u2003months. All children were anti\u2010HAV and anti\u2010HIV negative at baseline, and the haemophilic group did not differ from their siblings in alanine aminotransferase (ALT; 25 IU\u2003L<jats:sup>\u22121<\/jats:sup> vs. 22 IU\u2003L<jats:sup>\u22121<\/jats:sup>), or in age; 8.5\u2003years vs. 8.7\u2003years. The vaccine was well tolerated, with minor adverse events being similar between groups; 21 (47%) vs. 24 (58%), <jats:italic>P\u2003<\/jats:italic>&gt;\u20030.05. Local symptoms included soreness in 39 (45%), erythema in 25 (29%), swelling in 21 (24%), and bruising in six (7%), with no differences between groups. The proportion seroconverting to anti\u2010HAV IgG positive did not differ between groups; 98% vs. 97% at month 1; 82% vs. 93% at month 6; and 100% vs. 100% at month 8, respectively. The HAV geometric mean titre was lower in those with Haemophilia, 185 vs. 233 mIU\u2003mL<jats:sup>\u22121<\/jats:sup> at month 1; 68 vs. 94 mIU\u2003mL<jats:sup>\u22121<\/jats:sup> at month 6; and 584 vs. 1082 mIU\u2003mL<jats:sup>\u22121<\/jats:sup> at month 8, respectively. We conclude that Havrix<jats:sup>\u00ae<\/jats:sup> is safe and immunogenic when administered s.c. in children with Haemophilia.<\/jats:p>","DOI":"10.1046\/j.1365-2516.2000.00386.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T23:01:14Z","timestamp":1047423674000},"page":"98-103","source":"Crossref","is-referenced-by-count":22,"title":["Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with Haemophilia"],"prefix":"10.1111","volume":"6","author":[{"family":"Ragni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Lusher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Koerper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Manco\u2010Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Krause","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"1","article-title":"Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"45","author":"Centers for Disease Control and Prevention","year":"1996","journal-title":"Morbid Mortal Wkly Rep"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-6-199503150-00011"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-1-199401010-00001"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92938-C"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92089-X"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90326-C"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)93050-B"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510410040030"},{"key":"e_1_2_6_10_2","unstructured":"Medical and Scientific Advisory Committee.National Hemophilia Foundation Medical Bulletin1995;226."},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1055\/s-0038-1648904","article-title":"Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti\u2010HIV positive and negative hemophilic patients","volume":"72","author":"Santagostino E","year":"1994","journal-title":"Thromb Haemostas"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1995.tb00356.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1996.tb00008.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1996.tb00143.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-0934(93)90147-J"},{"key":"e_1_2_6_16_2","first-page":"545","article-title":"Antibody response to immunization of patients with hemophilia with and without evidence of HIV (HTLV\u2010III) infection","volume":"109","author":"Ragni MV","year":"1987","journal-title":"J Lab Clin Med"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05268.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1995.tb00344.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1996.tb01325.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199208133270702"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(97)00199-0"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2516.2000.00386.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2516.2000.00386.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2516.2000.00386.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T10:38:14Z","timestamp":1698575894000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2516.2000.00386.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,3]]}},"alternative-id":["10.1046\/j.1365-2516.2000.00386.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2516.2000.00386.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3]]}}}